VOTIS to Develop Device for Screening Peripheral Arterial Foot Disease for India
VOTIS Subdermal Imaging Technology (VOTIS) in Israel and ii Ventures Private Limited (iiV) in India will develop a system to screen mainly rural Indians for
Yarok Microbio Fast Testing to stop Food Recalls and Plant Pathogens
Jerusalem based Yarok MicroBio combines biochemicals with machine vision and digital image analysis to detect dangerous microbes, such as E.coli, Listeria, Salmonella in food products
Israeli Anti-Viral Mask Maker Sonovia Expands Global Marketing Campaign as It Completes IPO
Sonovia Ltd, which produces and markets masks made from the their anti-bacterial & antiviral fabrics, sees itself on the forefront of the fight against COVID-19.
OrCam Plans $3 billion Valuation in 2021 IPO
OrCam Technologies Ltd, founded and run by Prof Amnon Shashua and Ziv Aviram, is set to go public in New York during 2021, reported by
Nanox’s Next Generation Radiology Rocks the RSNA 2020!
NANO-X IMAGING LTD (NASDAQ: NNOX) successfully demonstrated its Nanox.ARC next-generation x-ray prototype at the 2020 annual conference of the Radiological Society of North America (RSNA),
Alpha TAU Medical raises $26 million funding as it moves to Jerusalem
Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, finished in June the closing of a Series B equity financing of $26
FDA Accepts Atox Bio’s Reltecimod to Treat Suspected Organ Dysfunction/Failure re “Flesh-Eating Disease”
The U.S. Food and Drug Administration (FDA) has accepted to Atox Bio’s filing of the New Drug Application (NDA) for Reltecimod with a Prescription Drug
Ascento Medical Gives New Hope for Alzheimer’s and Dementia Patients
Ascento Medical is a company in the field of Dementia and Alzheimer’s treatment & prevention, using Artificial Intelligence and Machine Learning to optimize a proven
KAHR Announces First Patient Dosed in DSP107 Treatment of Solid Tumors Phase 1/2 Clinical Trial
Jerusalem based KAHR MEDICAL, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, started treating the first patient in its Phase 1/2 clinical trial (NCT04440735)
